PRECISION BIOSCIENCES INC Segments Disclosure
| Years Ended December 31, | |||||||||||
| (in thousands) | 2025 | 2024 | |||||||||
| Revenue | $ | 34,264 | $ | 68,696 | |||||||
| Operating expenses | |||||||||||
| Research and development | |||||||||||
| Direct research and development expenses by product candidate: | |||||||||||
| PBGENE-HBV external development costs | 7,152 | 16,111 | |||||||||
PBGENE-DMD external development costs1 | 15,298 | 1,230 | |||||||||
| PBGENE-3243 external development costs | 3,103 | 9,808 | |||||||||
| Platform development and early-stage research expenses: | |||||||||||
| Employee-related costs (including share-based compensation) | 19,939 | 21,313 | |||||||||
| Laboratory supplies and services | 1,798 | 2,621 | |||||||||
| CMOs and outsourced research and development | 504 | 247 | |||||||||
| Facility-related costs, laboratory equipment, and maintenance | 2,841 | 3,082 | |||||||||
| Depreciation and amortization | 1,299 | 2,718 | |||||||||
| Licensing fees and other research and development costs | 2,238 | 2,429 | |||||||||
| Total research and development expenses | $ | 54,172 | $ | 59,559 | |||||||
| General and administrative expense | |||||||||||
| Employee-related costs (including share-based compensation) | 19,904 | 21,861 | |||||||||
| Consulting and professional services | 6,106 | 6,327 | |||||||||
| Other operating expenses and all other costs | 6,230 | 7,111 | |||||||||
| Total general and administrative expenses | $ | 32,240 | $ | 35,299 | |||||||
| Total operating expenses | $ | 86,412 | $ | 94,858 | |||||||
| Operating loss | (52,148) | (26,162) | |||||||||
| Total other income | 5,539 | 33,329 | |||||||||
| (Loss) income from continuing operations | $ | (46,609) | $ | 7,167 | |||||||
| Gain from discontinued operations | 885 | — | |||||||||
| Net (loss) income | $ | (45,724) | $ | 7,167 | |||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 12, 2026 | Showing above |
| 2024 | Mar 26, 2025 | |
| 2023 | Mar 27, 2024 | |
| 2022 | Mar 9, 2023 | |
| 2021 | Mar 15, 2022 | |
| 2020 | Mar 18, 2021 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.